TherapeuticsMD, Inc operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone561-961-1900
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$16.10 million
Profitability
Miscellaneous
Employees241
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
TherapeuticsMD (NASDAQ:TXMD) Frequently Asked Questions
What is TherapeuticsMD's stock symbol?
TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD."
How were TherapeuticsMD's earnings last quarter?
TherapeuticsMD Inc (NASDAQ:TXMD) posted its earnings results on Tuesday, August, 6th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.18) by $0.01. The firm earned $6.08 million during the quarter, compared to analyst estimates of $5.12 million. TherapeuticsMD had a negative net margin of 913.07% and a negative return on equity of 212.57%. TherapeuticsMD's revenue for the quarter was up 60.0% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.15) EPS. View TherapeuticsMD's Earnings History.
When is TherapeuticsMD's next earnings date?
What price target have analysts set for TXMD?
6 brokerages have issued 1-year target prices for TherapeuticsMD's shares. Their forecasts range from $3.00 to $13.00. On average, they anticipate TherapeuticsMD's stock price to reach $9.00 in the next year. This suggests a possible upside of 215.8% from the stock's current price. View Analyst Price Targets for TherapeuticsMD.
What is the consensus analysts' recommendation for TherapeuticsMD?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TherapeuticsMD.
What are Wall Street analysts saying about TherapeuticsMD stock?
Here are some recent quotes from research analysts about TherapeuticsMD stock:
- 1. According to Zacks Investment Research, "TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription and over-the-counter products targeted exclusively for women. It is developing three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. TherapeuticsMD, Inc. is based in Boca Raton, Florida. " (5/14/2019)
- 2. Cantor Fitzgerald analysts commented, "We reiterate our OW rating. The execution behind the launches of Annovera is underappreciated, in our view, and we think peak sales could exceed modest expectations for three drugs that target large unmet needs. Valuation Summary We use a blend of EV/EBITDA and DCF analysis to arrive at our 12-month PT of $27. The Disclosure Section may be found on pages 3 – 4.Valuation We use a blend of EV/EBITDA and DCF analysis to arrive at our 12-month PT of $27." (1/21/2019)
Has TherapeuticsMD been receiving favorable news coverage?
News coverage about TXMD stock has been trending positive recently, according to InfoTrie. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. TherapeuticsMD earned a news sentiment score of 2.5 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the company's share price in the immediate future. View News Stories for TherapeuticsMD.
Who are some of TherapeuticsMD's key competitors?
Some companies that are related to TherapeuticsMD include Amicus Therapeutics (FOLD), Genmab A/S (GMAB), Myokardia (MYOK), Agios Pharmaceuticals (AGIO), Reata Pharmaceuticals (RETA), Xencor (XNCR), Zai Lab (ZLAB), Zogenix (ZGNX), Emergent Biosolutions (EBS), Uniqure (QURE), Intercept Pharmaceuticals (ICPT), Akcea Therapeutics (AKCA), Cambrex (CBM), Portola Pharmaceuticals (PTLA) and Biohaven Pharmaceutical (BHVN).
What other stocks do shareholders of TherapeuticsMD own?
Who are TherapeuticsMD's key executives?
TherapeuticsMD's management team includes the folowing people:
- Mr. Robert G. Finizio, Co-Founder, CEO & Director (Age 48)
- Mr. John C. K. Milligan IV, Pres, Sec. & Director (Age 57)
- Dr. Brian A. Bernick, Co-Founder, Chief Clinical Officer & Director (Age 51)
- Mr. Daniel Alan Cartwright, CFO & Treasurer (Age 61)
- Mr. Mitchell L. Krassan, Exec. VP & Chief Strategy Officer (Age 53)
Who are TherapeuticsMD's major shareholders?
TherapeuticsMD's stock is owned by many different of institutional and retail investors. Top institutional investors include Price T Rowe Associates Inc. MD (9.11%), Bank of New York Mellon Corp (8.77%), BlackRock Inc. (6.63%), Vanguard Group Inc. (6.04%), Bamco Inc. NY (1.38%) and AXA (1.33%). Company insiders that own TherapeuticsMD stock include Angus C Russell, Brian Bernick, Daniel A Cartwright, Jane F Barlow, John CK Iv Milligan, Jules A Musing, Robert G Finizio and Tommy G Thompson. View Institutional Ownership Trends for TherapeuticsMD.
Which institutional investors are selling TherapeuticsMD stock?
TXMD stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Morgan Stanley, Price T Rowe Associates Inc. MD, BNP Paribas Arbitrage SA, TD Asset Management Inc., Commonwealth Equity Services LLC, Wells Fargo & Company MN and Cubist Systematic Strategies LLC. Company insiders that have sold TherapeuticsMD company stock in the last year include Brian Bernick, Daniel A Cartwright, John CK Iv Milligan, Jules A Musing and Robert G Finizio. View Insider Buying and Selling for TherapeuticsMD.
Which institutional investors are buying TherapeuticsMD stock?
TXMD stock was purchased by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, C WorldWide Group Holding A S, Invesco Ltd., Bamco Inc. NY, Nuveen Asset Management LLC, Vanguard Group Inc., Carlson Capital L P and BlackRock Inc.. Company insiders that have bought TherapeuticsMD stock in the last two years include Angus C Russell, Brian Bernick, Jane F Barlow, John CK Iv Milligan, Robert G Finizio and Tommy G Thompson. View Insider Buying and Selling for TherapeuticsMD.
How do I buy shares of TherapeuticsMD?
Shares of TXMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is TherapeuticsMD's stock price today?
One share of TXMD stock can currently be purchased for approximately $2.85.
How big of a company is TherapeuticsMD?
TherapeuticsMD has a market capitalization of $687.48 million and generates $16.10 million in revenue each year. The company earns $-132,620,000.00 in net income (profit) each year or ($0.59) on an earnings per share basis. TherapeuticsMD employs 241 workers across the globe.View Additional Information About TherapeuticsMD.
What is TherapeuticsMD's official website?
How can I contact TherapeuticsMD?
TherapeuticsMD's mailing address is 6800 BROKEN SOUND PARKWAY NW, BOCA RATON FL, 33487. The company can be reached via phone at 561-961-1900 or via email at [email protected]
MarketBeat Community Rating for TherapeuticsMD (NASDAQ TXMD)
MarketBeat's community ratings are surveys of what our community members think about TherapeuticsMD and other stocks. Vote "Outperform" if you believe TXMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TXMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
